<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494257</url>
  </required_header>
  <id_info>
    <org_study_id>58/15.02.2018/5104</org_study_id>
    <nct_id>NCT03494257</nct_id>
  </id_info>
  <brief_title>Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification</brief_title>
  <official_title>Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of fixed brinzolamide-brimonidine combination on
      intaocular pressure after uncomplicated phacoemulsification surgery.

      Patients scheduled for phacoemulsification will be randomly assigned to 1 of 2 groups.

      The treatment group will receive 1 drop of brimonidine-brinzolamide fixed combination
      immediately after surgery, and the control group will receive no treatment. The IOP will be
      measured preoperatively and at 6, 12, and 24 hours postoperatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phacoemulsification with the use of an ophthalmic viscosurgical device (OVD) and implantation
      of a foldable intraocular lens (IOL) is the preferred technique for cataract surgery today.

      OVDs in spite of their advantages in phacoemulsification surgery, have been correlated with
      intraocular pressure (IOP) increase within the first 24 hours postoperatively. This
      constitutes a frequent short-term complication of cataract surgery and can lead to corneal
      edema and pain. This IOP rise may also increase the risk of retinal artery occlusion,
      ischemic optic neuropathy, and deterioration of preexisting glaucomatous nerve damage.

      DuoVisc, an OVD that consists of Viscoat (chondroitin sulfate 4.0%-sodium hyaluronate 3.0%)
      in combination with Provisc (sodium hyaluronate 1.0%) is the most frequently used OVD during
      cataract surgery.

      To prevent IOP spikes postoperatively, various antiglaucoma agents have been used.
      Brinzolamide is a carbonic anhydrase inhibitor that acts upon the ciliary processes and
      reduces aqueous humor secretion.Brimonidine is a highly selective a2-adrenergic agonist that
      increases uveoscleral outflow and reduces aqueous humor production.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Actual">April 6, 2018</completion_date>
  <primary_completion_date type="Actual">March 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized double-masked comparative study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Patients will be unaware of their groupe assignment. The investigator who will measure the IOP will also be masked to group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IOP at 6 hours after surgery</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>IOP will be measured by the same Goldman applanation tonometer used preoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP at 12 hours after surgery</measure>
    <time_frame>12 hours postoperatively</time_frame>
    <description>IOP will be measured by the same Goldman applanation tonometer used preoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP at 24 hours after surgery</measure>
    <time_frame>12 hours postoperatively</time_frame>
    <description>IOP will be measured by the same Goldman applanation tonometer used preoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Cataract</condition>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Brinzolamide-Brimonidine fixed combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No topical IOP reducing medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No IOP reducing drops instilled after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide-Brimonidine fixed combination</intervention_name>
    <description>Simbrinza 0.2%-1% Ophthalmic Suspension</description>
    <arm_group_label>Brinzolamide-Brimonidine fixed combination</arm_group_label>
    <other_name>Simbrinza, 0.2%-1% Ophthalmic Suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo cataract surgery by phacoemulsification.

        Exclusion Criteria:

          -  previous ocular surgery

          -  ocular hypertension

          -  pseudoexfoliation syndrome

          -  pigment dispersion syndrome

          -  glaucoma

          -  history of severe cardiovascular disease, cerebral or coronary insufficiency,
             depression, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis
             obliterans

          -  hypersensitivity to sulfonamides or brimonidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine Georgakopoulos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical School, University of Patras, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <state>Achaia</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Patras</investigator_affiliation>
    <investigator_full_name>Constantinos D. Georgakopoulos, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>phacoemulsification</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>cataract</keyword>
  <keyword>brinzolamide</keyword>
  <keyword>brimonidinde</keyword>
  <keyword>fixed combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

